When Michelle Dipp and Jennifer Lum determined to launch a life sciences progress fairness fund two years in the past, the market regarded very totally different.
The Covid-19 pandemic was driving traders in droves to biotech and pharma firms. Automation and drug manufacturing had been turning into scorching subjects.
